Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

In Connecticut, where Medicaid has clamped down on covering GLP-1 medications for obesity, people are looking ... visits thinking their medications are approved by the Food and Drug Administration ...

The governor also said she would work with other states to leverage their combined purchasing power to reduce the cost of the ...

strengthening its case for coverage as Medicare cannot cover obesity drugs unless they are approved for a secondary use by the Food and Drug Administration. Commercial insurers and employers were ...